Compare SFST & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFST | MRVI |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.7M | 472.8M |
| IPO Year | 2012 | 2020 |
| Metric | SFST | MRVI |
|---|---|---|
| Price | $58.85 | $3.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $64.00 | $4.13 |
| AVG Volume (30 Days) | 97.5K | ★ 1.9M |
| Earning Date | 04-21-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.76 | 14.29 |
| EPS | ★ 3.72 | N/A |
| Revenue | $6,282,000.00 | ★ $185,743,000.00 |
| Revenue This Year | $10.47 | $12.44 |
| Revenue Next Year | $12.19 | $7.90 |
| P/E Ratio | $15.73 | ★ N/A |
| Revenue Growth | ★ 12.99 | N/A |
| 52 Week Low | $30.68 | $1.67 |
| 52 Week High | $62.00 | $4.11 |
| Indicator | SFST | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 67.46 | 57.59 |
| Support Level | $50.36 | $3.25 |
| Resistance Level | $61.53 | $3.93 |
| Average True Range (ATR) | 1.55 | 0.16 |
| MACD | 0.65 | 0.04 |
| Stochastic Oscillator | 90.91 | 86.11 |
Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.